Please ensure Javascript is enabled for purposes of website accessibility

Why Bausch Health Companies Is Plunging Today

By Zhiyuan Sun – Aug 3, 2021 at 3:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The turnaround isn't happening as fast as investors expected.

What happened

Investors of healthcare giant Bausch Health Companies (BHC 0.89%) are having a rather rainy afternoon. Shares are down 11%, to $26.32, as of 2:30 p.m. EDT, after the company announced disappointing guidance in its second-quarter earnings.

During the quarter, Bausch Health improved its revenue by 26% year over year to $2.1 billion. Simultaneously, its operating income less non-cash items (EBITDA, or earnings before interest, taxes, depreciation, and amortization) increased 33% to $826 million. However, due to asset divestitures, product recalls, and unfavorable foreign currency movements, the company lowered its revenue guidance for the year by $200 million in the range of $8.4 to $8.6 million. In addition, Bausch Health is spinning off its dermatology laser hardware Solta Medical subsidiary into an independent publicly traded company.

Doctor holding paperwork in front of patients.

Image source: Getty Images.

So what 

Bausch Health is knee-deep in debt. The leveraged acquisitions of its present day eye care, gastrointestinal, and dermatology drug businesses added $24.6 billion in liabilities on its balance sheet. That's about eight times the EBITDA the company generated in the last 12 months. Shareholders clearly didn't appreciate the downside revenue guidance when it is in dire need of growth. What's more, the Solta Medical spinoff will raise cash for the parent company at the expense of divesting about $253 million in annual revenue in the process.

Now what 

The stock already has a big part of its risks priced in. As a matter of fact, it is trading for just 6.3 times earnings. The cheap valuation has attracted billionaire hedge fund investors like Carl Icahn, who are betting that Bausch Health can turn things around. Hence, investors on the hunt for bargains should consider buying today's dip as an opportunity for entry. But stay current on liquidity developments surrounding the healthcare stock.  

Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bausch Health Companies. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Stock Quote
Bausch Health Companies
$6.82 (0.89%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.